NEW YORK (GenomeWeb) – Roche today announced that its cobas HSV 1 and 2 assay has received 510(k) clearance from the US Food and Drug Administration.

The dual target test detects and differentiates herpes simplex virus 1 and 2 DNA in symptomatic patients' anogenital specimens. 

Differentiating HSV-1 from HSV-2 can impact patient management and treatment, but herpes lesions can be confused with other conditions. Molecular testing is faster and is considered more sensitive than traditional viral culture. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

US News & World Report writes that genetic testing of lung tumors can help identify treatments for patients.

A team of researchers plans to sample Loch Ness for environmental DNA, according to Newsweek.

The New York Times writes about the appearance of mosaicism in healthy people.

In PNAS this week: insecticide resistance patterns Anopheles gambiae mosquito, transcriptome patterns in Pseudomonas aeruginosa during infection, and more.

Jun
19
Sponsored by
ACD

This webinar will provide evidence for the use of RNA in situ hybridization (RNA ISH) as a replacement for immunohistochemistry (IHC) in cancer research and diagnostic applications.

Jun
21
Sponsored by
Roche

This webinar will provide a detailed look at how a genomics lab implemented next-generation sequencing (NGS) liquid biopsy assays into its in-house clinical research program.